Q-omics provides the consensus-scored ANKRD20A11P profile across patient tissues and cancer cell-line models. ANKRD20A11P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, ANKRD20A11P is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, ANKRD20A11P RNA expression shows 16,371 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BRCA, HNSC, and THYM as cancer lineages where ANKRD20A11P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD20A11P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD20A11P survival associations across molecular data types. ANKRD20A11P RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD20A11P RNA expression–survival associations across cancer types. High ANKRD20A11P expression shows unfavorable associations in UCEC, KIRC, THCA and KIRP, but favorable associations in BRCA and HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for ANKRD20A11P RNA expression.
This table summarizes ANKRD20A11P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD20A11P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD20A11P shows lower tumor expression in HNSC, COAD, KICH, LUAD and LUSC and higher tumor expression in CHOL. The HNSC box plot shows higher ANKRD20A11P RNA expression in normal versus tumor tissue (log2 FC = −0.947, t-test p < 0.001).
This table shows molecular features associated with ANKRD20A11P in patient tissues and cancer cell lines. In patient samples, ANKRD20A11P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD20A11P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE.
